[The effect of neurotrophic treatment on the activation of reparative processes in patients with acute traumatic brain injury].

Selianina NV, Karakulova IuV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2012Cited by 2 (Europe PMC)

PMID22951781PepBankPUB-22951781

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In patients with middle brain injuries, neurological symptom severity decreased after complex treatment that included Cerebrolysin.
In plain wordsIn patients with middle brain injuries, neurological symptom severity decreased after treatment that included Cerebrolysin, compared with before treatment.
Peptide
Cerebrolysin
Outcome
DecreaseNeurological symptom severity
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
After the treatment, there were the decrease in the severity of neurological symptoms and a significant positive dynamics on the FAB scale as well as the increase in blood BDNF and serotonin levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The complex study of cognitive and emotional status, levels of serum serotonin and brain-derived neurotrophic factor (BDNF) were performed in 72 patients with acute traumatic brain injury, with a special focus on middle brain injuries (MBI), treated with Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2295178101
02HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In patients with middle brain injuries, FAB performance showed significant improvement after complex treatment that included Cerebrolysin.
In plain wordsIn patients with middle brain injuries, FAB performance showed significant improvement after treatment that included Cerebrolysin, compared with before treatment.
Peptide
Cerebrolysin
Outcome
IncreaseFAB scale
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
After the treatment, there were the decrease in the severity of neurological symptoms and a significant positive dynamics on the FAB scale as well as the increase in blood BDNF and serotonin levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The complex study of cognitive and emotional status, levels of serum serotonin and brain-derived neurotrophic factor (BDNF) were performed in 72 patients with acute traumatic brain injury, with a special focus on middle brain injuries (MBI), treated with Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2295178102
03HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism
In patients with middle brain injuries, blood BDNF increased after complex treatment that included Cerebrolysin.
In plain wordsIn patients with middle brain injuries, blood BDNF increased after treatment that included Cerebrolysin, compared with before treatment.
Peptide
Cerebrolysin
Outcome
IncreaseBlood BDNF
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Nervous system and cognition
Source sentences
Summary
After the treatment, there were the decrease in the severity of neurological symptoms and a significant positive dynamics on the FAB scale as well as the increase in blood BDNF and serotonin levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The complex study of cognitive and emotional status, levels of serum serotonin and brain-derived neurotrophic factor (BDNF) were performed in 72 patients with acute traumatic brain injury, with a special focus on middle brain injuries (MBI), treated with Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2295178103
04HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism
In patients with middle brain injuries, blood serotonin increased after complex treatment that included Cerebrolysin.
In plain wordsIn patients with middle brain injuries, blood serotonin increased after treatment that included Cerebrolysin, compared with before treatment.
Peptide
Cerebrolysin
Outcome
IncreaseBlood serotonin
Study
n: not reported in source
Outcome group
Neurotransmitters and neurotrophic factors · Nervous system and cognition
Source sentences
Summary
After the treatment, there were the decrease in the severity of neurological symptoms and a significant positive dynamics on the FAB scale as well as the increase in blood BDNF and serotonin levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The complex study of cognitive and emotional status, levels of serum serotonin and brain-derived neurotrophic factor (BDNF) were performed in 72 patients with acute traumatic brain injury, with a special focus on middle brain injuries (MBI), treated with Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2295178104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.